Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?

References

• De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 28(11), 482–490 (2007).
   PubMed Web of Science ®Google Scholar
• De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes.” Blood 112(8), 3303–3311 (2008).
   PubMed Web of Science ®Google Scholar
• De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin. Immunol. 131(2), 189–201 (2009).
   PubMed Web of Science ®Google Scholar
• Cousens LP, Jawa V, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin. Immunol. (2013) (In Press).
   Google Scholar
• De Groot AS, Terry F, Cousens LP, Martin W. Beyond Humanization and De-immunization: tolerization as a method for reducing the immunogenicity of biologics. Exp. Rev. Clin. Pharmacol. (2013) (In Press).
   Google Scholar
• Cousens LP, Tassone R, Mazer BD, Ramachandiran V, Scott DW, De Groot AS. Tregitope update: mechanism of action parallels IVIg. Autoimmun. Rev. 12(3), 436–443 (2012).
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787–2794 (2011).
   PubMed Web of Science ®Google Scholar
• Ephrem A, Chamat S, Miquel C et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111(2), 715–722 (2008).
   PubMed Web of Science ®Google Scholar
• Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J. Rheumatol. 39(5), 1019–1025 (2012).
   PubMed Web of Science ®Google Scholar
• Schwab I, Nimmerjahn F Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13(3), 176–189 (2013).
   PubMed Web of Science ®Google Scholar
• Soukhareva N, Jiang Y, Scott DW. Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell Immunol. 240, 41–46 (2006).
   PubMedGoogle Scholar
• Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 38(2):123–137 (2005).
   PubMed Web of Science ®Google Scholar
• Jordan SC, Toyoda, M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev. Clin. Immunol. 7(3), 341–348 (2011).
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long-Term Therapy with Intravenous Immunoglobulin is Beneficial in Patients with Autoimmune Diseases. Clin. Rev. Allergy Immunol. 42(2), 247–255 (2012).
   PubMedGoogle Scholar
• Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus 18(10), 884–888 (2009).
   PubMedGoogle Scholar
• Dykes AC, Walker ID, Lowe GD, Tait RC. Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review. Haemophilia 7(2), 160–163 (2001).
   PubMedGoogle Scholar
• Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin. Hematol. 46(1 Suppl. 2), S2–S14 (2009).
   PubMed Web of Science ®Google Scholar
• Lozeron P, Adams D. Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010. J. Neurol. 258(9), 1737–1741 (2011).
   PubMedGoogle Scholar
• Rajabally YA, Mahdi-Rogers M. Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins. Biologics 4, 45–49 (2010).
   PubMedGoogle Scholar
• Cousens LP, Najafian N, Mingozzi F et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity. J. Clin. Immunol. 33(1), 43–49 (2013).
   Google Scholar
• Cousens LP, Su Y, McClaine E et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J. Diabetes Res. 2013, 621693 (2013).
   PubMed Web of Science ®Google Scholar
• Su Y, Rossi R, De Groot AS, Scott DW. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicityper se. J. Leukoc. Biol. 94(2), 377–383 (2013).
   PubMed Web of Science ®Google Scholar
• Hui DJ, Basner-Tschakarjan E, Chen Y et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol Ther. 21(9), 1727–1737 (2013).
   PubMed Web of Science ®Google Scholar
• Cousens LP, Mingozzi F, van der Marel S et al. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease. Hum. Vaccin. Immunother. 8(10), 1459–1464 (2012).
   PubMed Web of Science ®Google Scholar
• Moise L, Gutierrez AH, Bailey-Kellogg C et al. The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix. Hum. Vaccin. Immunother. 9(7), 1577–1586 (2013).
   PubMed Web of Science ®Google Scholar
• Hahn BH, Singh RP, La Cava A, Ebling FM. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J. Immunol. 175(11), 7728–7737 (2005).
   PubMedGoogle Scholar
• Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc. Natl Acad. Sci. USA 103(23), 8810–8815 (2006).
   Google Scholar
• Sharabi A, Dayan M, Zinger H, Mozes E. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. J. Clin. Immunol. 30(1), 34–44 (2010).
   PubMedGoogle Scholar